Financial Data and Key Metrics Changes - Q3 2024 reported revenues increased 16.4% year-over-year to $864.4 million, with organic revenue growth of 3.1% and a currency tailwind of 0.7% [16][35] - Non-GAAP operating margin was 14.9%, down 510 basis points year-over-year, primarily due to recent strategic acquisitions [17][35] - GAAP diluted EPS was $0.27, compared to $0.60 in Q3 2023, while non-GAAP diluted EPS was $0.60, down 18.9% from $0.74 in Q3 2023 [18][35] Business Line Data and Key Metrics Changes - Bruker BioSpin Group revenue was $633 million, growing in the high-teens percentage, with strong contributions from automation and services [22] - Bruker CALID Group revenue was $773 million, with low-double-digit CER revenue growth, driven by microbiology and infectious disease diagnostics [23] - Bruker NANO revenue was $780 million, with mid-teens percentage CER revenue growth, supported by semiconductor metrology [24] - BEST segment CER revenues grew in the low-single digits, driven by research instruments and technology for semiconductor lithography [25] Market Data and Key Metrics Changes - Americas revenue grew in the low-single digits, while Asia-Pacific revenue (excluding China) was up double-digit percentage [40] - China revenue declined low double-digits, and European revenue declined low single-digit percentage year-over-year [40] - EMEA region revenue was up mid-teens percentage year-over-year [40] Company Strategy and Development Direction - The company is focused on integrating and improving recently acquired businesses to drive above-market organic revenue growth and significant margin expansion in 2025 and beyond [15][33] - Strategic expansion into single-cell spatial molecular diagnostics and lab automation is expected to contribute to profitable growth [33] Management's Comments on Operating Environment and Future Outlook - Management noted that delayed recoveries in biopharma and China demand will not significantly benefit fiscal year 2024, leading to a lowered guidance [14][45] - The company anticipates low-single-digit organic revenue growth in Q4 2024, following a strong Q4 2023 [49] - Management expressed optimism about stimulus orders from China and improvements in biopharma demand in 2025 [63][64] Other Important Information - The company is adjusting its fiscal year 2024 guidance to a revenue range of $3.34 billion to $3.37 billion, with organic revenue growth of 3% to 4% [46] - Non-GAAP EPS guidance for fiscal year 2024 is now in the range of $2.36 to $2.41, down from a prior range of $2.59 to $2.64 [48] Q&A Session Summary Question: Impact of biopharma and China on guidance cut - Management indicated that the guidance cut is primarily due to a significant decline in China orders, which are down approximately 20% year-over-year, and slower recovery in biopharma [55][56] Question: Outlook for 2025 - Management acknowledged that estimates for 2025 would likely be lowered due to the current weakness in biopharma and China, with no specific guidance provided yet [58][64] Question: Confidence in above-market growth - Management expressed confidence in above-market growth driven by strong demand in diagnostics and semiconductor metrology, despite current challenges [61][66] Question: Book-to-bill ratio and order dynamics - The book-to-bill ratio for Q3 was below 1, but organic bookings growth in BSI was the best in several quarters, indicating positive momentum despite challenges in China and biopharma [88][89] Question: Margin dilution from acquisitions - Management confirmed that acquisition integration is on track, with expectations for significant margin improvement in the coming years [72][74]

Exhibit 99.1 Bruker Reports Third Quarter 2024 Financial Results • Q3 2024 revenues of $864.4 million, up 16.4% year-over-year (yoy); Bruker organic revenue up 3.1% yoy, and CER revenue up 15.7% yoy; BSI segment organic revenue up 3.8% yoy • Q3 2024 GAAP diluted EPS $0.27; non-GAAP diluted EPS $0.60 • Updated FY2024 guidance: o Revenue $3.34 to $3.37 billion, implying Bruker organic revenue growth of 3% to 4%, and CER revenue growth of approximately 13% yoy o Non-GAAP EPS of $2.36 - $2.41 BILLERICA, Massach ...

Biognosys' proprietary P2 Plasma Enrichment System enables plasma proteome profiling with unprecedented depth and throughput, both as contract research and in-house via licensing By offering the combination of NULISA™ affinity-based assays and TrueDiscovery® mass spectrometry-based plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry's most comprehensive solutions for plasma proteomics Spectronaut® workflows for high-performance computing environments, post-translational modifications, ...

Bruker Corporation (BRKR) recently announced the release of its latest innovative neuroscience research solution, the OptoVolt module, at the Neuroscience 2024 conference. The module uniquely addresses the challenges of voltage imaging by providing scanner technology. The latest release expands Bruker's Ultima multiphoton microscope platform with advanced neuroscience research capabilities. BRKR's Likely Stock Trend Following the News Subsequent to the news, the share price of BRKR moved south 1.6% to $65.9 ...

Bruker Corporation's (BRKR) growth is backed by strong sales within its X-Ray and Nano Analytics businesses. Within the PCI division, expanding customer demand for pre-clinical MRI systems is highly encouraging. Meanwhile, the impact of macroeconomic pressure and currency fluctuation is likely to hurt the company's operational results. In the past year, this Zacks Rank #3 (Hold) company's shares have gained 10.4% compared with the industry's 27.5% growth and the S&P 500 composite's 34.9% gain. This renowned ...

Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Diagnostic Devices Market (2024 Edition): Analysis by Type (Imaging Devices, Microscopes, Immunoassays, Molecular Diagnostics, Others), Application, End-user and Region: Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering. This report provides a complete analysis of the Global Dermatology Diagnostic Devices industry for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 202 ...

It has been about a month since the last earnings report for Bruker (BRKR) . Shares have added about 6.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Bruker due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Bruker Q2 Earnings Meet Estimates, Revenues Rise Y/Y B ...

Bruker Corporation's (BRKR) BioSpin Group has been witnessing impressive growth in its end markets and the strategic buyout of Chemspeed is poised to expand its potential. Within BSI Nano, AI is driving significant growth in the semiconductor and metrology tools. The latest innovations and acquisitions in the CALID business uphold its robust growth prospects. Meanwhile, the impact of macroeconomic pressure and competitive challenges may hurt the company's operational results. In the past year, this Zacks Ra ...

Under a strategic partnership with Alamar Biosciences, Biognosys is a provider of choice of NULISA multiplex assay services for biopharma research The NULISAseq™ CNS Disease and Inflammation panels are now available for customers as a contract research service from Biognosys' high-end proteomics facility in Europe By offering the combination of NULISA affinity-based assays and TrueDiscovery® mass spectrometrybased plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry's most comprehensive ...

Bruker Corporation (BRKR) recently announced the successful installation and acceptance of a 1.2 GHz Avance Nuclear Magnetic Resonance ("NMR") spectrometer at the Korea Basic Science Institute ("KBSI"). As the first 1.2 GHz NMR system in the Asia-Pacific region, the solution has set a new benchmark for molecular, cell biology and disease research by ultra-high field NMR. The latest development from the company arrives right before the 30 ICMRBS (International Conference on Magnetic Resonance in Biological S ...